All In Biotech

Drug Trial Radar · NCT06885840

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Apr 2028

Study completion Sep 2028

Sponsor

Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • MCLA-129Drug

    MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • Foshan First People's Hospital

    Foshan, Guangdong, China

  • Guangdong General Hospital

    Guangzhou, Guangdong, China

  • Hebei University Affiliated Hospital

    Baoding, Hebei, China

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nantong Cancer Hospital

    Nantong, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.